November 12, 2018Thrombosis and Haemostasis
Asymptomatic Deep Vein Thrombosis is Associated with an Increased Risk of Death: Insights from the APEX Trial
View Full Paper
Ask AI
Bookmark
Share
Why the study?
Does extended-duration betrixaban reduce asymptomatic DVT compared to enoxaparin, and is asymptomatic DVT associated with increased mortality in acutely ill hospitalized medical patients?
Population
7,513 acutely ill hospitalized medical patients
Comparison
Extended-duration betrixaban (35–42 days) vs Enoxaparin (10 ± 4 days)
Design
RCT, randomly assigned
Follow-up
through 77 days
Authors
Discussion
Loading...
Member takes
Implication
Asymptomatic DVT signals elevated short-term mortality risk in medical inpatients; extends RCT evidence on its prognostic value.
Structured PICO
Does extended-duration betrixaban reduce asymptomatic DVT compared to enoxaparin, and is asymptomatic DVT associated with increased mortality in acutely ill hospitalized medical patients?
P
Population
7,513 acutely ill hospitalized medical patients
I
Intervention
Extended-duration betrixaban (35–42 days)
C
Comparator
Enoxaparin (10 ± 4 days)
O
Outcome
Asymptomatic deep vein thrombosis (DVT) assessed once with compression ultrasound between day 32 and 47, and all-cause mortality assessed through 77 dayshard clinical
In acutely ill hospitalized medical patients, asymptomatic DVT detected by compression ultrasound is associated with a nearly threefold increased risk of short-term all-cause mortality.
Cite This Study
Kalaycı et al. (2018) studied this question.
Topics
View Full Paper
Ask AI
Bookmark
Share